Trim EMR 10-15% ahead of November Q4 FY26 catalyst, retaining 85-90% core with $142.90 hard stop
Underweight rating with 10-15% trim is the disciplined middle path per 9/28 reflection calibration—aggressive 20-30% trim forfeits upside that structural anchors (200 SMA at $143, dividend Aristocrat floor) defend, while pure Hold bleeds alpha in this stretched setup with 1:1 risk/reward and weak volume confirmation. Hard stop $142.90; weekly close below $141.50 forces full exit. Retained 85-90% core preserves participation if November print confirms forward EPS bridge toward $7.26 consensus target.
| Position | Action |
|---|---|
| Pre-catalyst positioning (ahead of November Q4 FY26 print) | Trim 10-15% of EMR position |
| Core position maintenance | Retain 85-90% as core with structural defense (200 SMA at $143, dividend Aristocrat floor) |
| If protective puts at $150 strike available at <3% position carry | Consider as binary catalyst hedge rather than additional trim |
EMR is a structurally improving business with inflecting earnings, a bullish technical posture, and the most important catalyst of the year sitting 4–6 weeks away — making it a stock to own into the print rather than fade.
| Indicator | Value | Signal |
|---|---|---|
| close_10_ema | 153.27 | bullish |
| close_50_sma | 152.60 | bullish |
| close_200_sma | 143.26 | bullish |
| macd | 0.51 | bullish |
| macd_signal | -0.41 | bullish |
| macd_histogram | +0.92 | bullish |
| rsi | 60.99 | bullish |
| bollinger_upper | 157.91 | neutral |
| bollinger_middle | 151.18 | neutral |
| bollinger_lower | 144.46 | neutral |
| atr | 3.67 |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Confirmed daily close above $164.31 on volume >2.5M (50-day average + breakout threshold)
Then: Add position on confirmed breakout
Forward P/E of 21.7x is reasonable given artificially depressed TTM earnings from restructuring charges
EV: +R1: 164.31 (Aug-5 swing high retest); +R2: 170+ on measured-move breakout · concedes: EMR is volatile; Macro is hawkish; TTM P/E looks rich at first glance (34.4x); FY-end blackout until early-to-mid November means no near-term news catalyst; Net debt of $10.93B is elevated
EMR lacks margin of safety at current levels: the technical setup is stretched at the upper Bollinger Band with VWMA divergence, valuation is premium even under bull-case EPS assumptions, macro headwinds (hawkish Fed, strong dollar, high long-end yields) create real cyclical pressure on EMR's process-industry end markets, and the FY26 catalyst offers roughly symmetric risk/reward rather than asymmetric upside.
· concedes: EMR is a quality compounder with genuine restructuring thesis; The AI/data-center capex opportunity is real, just small relative to total revenue; Competitive moat in automation is genuine, just not as wide as the bull claims vs. true automation peers
→ vs conservative: Waiting for 152.60 pullback to 50 SMA sacrifices 7-12% opportunity cost; strong trends often don't retest the 50 SMA for weeks/months while price runs to new highs
→ vs conservative: By the time the 152.60 pullback arrives (if ever), stock may already be at 165-170 after breaking out through 164.31
→ vs conservative: Classic trap of letting great setups walk away over a 2% drawdown fear that turns 20% annualized returns into 8%
→ vs neutral: TTM P/E of 34.4x is not the relevant number—forward P/E of 21.7x is the right framework; TTM captures trough earnings distorted by restructuring charges
→ vs neutral: Saying 'valuation is full' at the moment of inflection is buying yesterday's setup; restructuring charges rolling off and divestitures cleaned up portfolio
→ vs neutral: Trimming 20-30% ahead of FY26 Q4 print means selling highest-conviction name right before it proves the thesis—this is performance anxiety, not risk management
→ vs conservative: Volume concern misread—VWMA bottoming at 149.3 on September 18 and turning up alongside price is early stage of volume confirmation, not divergence
→ vs neutral: Macro concerns (96% probability of no Fed cuts in 2026, 30-year yields at 24-year highs) already priced in; EMR at 158 because underlying business is good enough to overcome them
→ vs conservative: Waiting for yield stabilization when yields stabilize and EMR may already be at 165—sacrificing 4-5% upside for a hedge that may never come
→ vs conservative: Sitting in cash waiting for 152.60 pullback is how you underperform; 10 EMA at 153.27 is a better entry than waiting for the dream scenario that probably doesn't arrive
| vwma | 150.87 | bullish |
Support: 153.27 · 152.6 · 143.26 | Resistance: 159.87 · 164.31
EMR has reclaimed its 50/200-day moving averages and is pushing into the upper Bollinger Band following a V-shaped recovery from the September 16 low of 145.83 (+8.5% in seven sessions). The MACD has produced a fresh bullish crossover with histogram printing +0.92, the first such trigger since late July. RSI sits at 60.99 in the constructive-but-not-overbought zone, ATR reads 3.67 (~2.3% daily volatility), and VWMA is turning higher at 150.87 to confirm genuine volume participation in the rebound. Recommended posture is trend-following longs on pullbacks toward 153.27 or 152.60 with invalidation below 152.60, targeting 164.31 and 170+ on breakout.
Market Cap
$87.7B
P/E (TTM)
34.4
Forward P/E
21.7
PEG Ratio
1.84
P/B
4.30
EPS (TTM)
$4.57
Forward EPS
$7.26
Dividend Yield
1.39%
Beta
1.233
52W Range
$122.64 – $166.35
50-Day MA
$153.20
200-Day MA
$144.21
Gross Margin
~52.8% (FY25)
EBITDA Margin
~26.9% (FY25)
Operating Margin (TTM)
~26.9%
Operating Margin (FY25)
~19.6%
Net Profit Margin
13.8% (TTM)
ROE
12.8%
ROA
6.9%
Total Assets
$42.21B
Total Debt
$13.26B
Net Debt
$10.93B
Debt/Equity
0.65
Current Ratio
0.90
Goodwill & Intangibles
$26.81B
Net Tangible Assets
-$6.43B
TTM FCF
$3.7B
TTM CapEx
~$0.45B
TTM Dividends + Buybacks
~$2.15B
Net Debt/EBITDA
~2.0x
Revenue 3Y CAGR
~9.3%
EBITDA 3Y CAGR
~11.4%
Q3 FY26 Revenue
$4.87B
Q3 FY26 Operating Income
$1.11B
Q3 FY26 Net Income
$718M
Q3 FY26 Diluted EPS
$1.28
Q3 FY26 FCF
$1.32B
FY25 Revenue
$18.02B
FY25 EBITDA
$4.84B
FY25 Net Income
$2.29B
FY25 Diluted EPS
$4.04
Annual Restructuring Charges
~$350-440M
Strengths
Concerns
Emerson Electric is a high-quality industrial compounder with best-in-class margins (53% gross, 27% EBITDA) and strong FCF generation ($3.7B TTM) following its portfolio transformation into focused automation solutions. The company trades at a premium 34.4x TTM P/E but offers a reasonable 21.7x forward P/E if the implied 59% EPS recovery materializes as restructuring benefits materialize; Q3 FY26 showed encouraging sequential acceleration with record revenue and margins. Key risks include elevated goodwill (63% of assets), moderate leverage (net debt/EBITDA ~2.0x), premium valuation with limited near-term upside, and dependence on restructuring execution to justify the ambitious forward earnings targets.
Macro: Hawkish regime with rising yields despite softer oil and dovish Fed speeches. The 30-year Treasury printed a 24-year high, the dollar hit a 16-month high vs. euro and Swiss franc, and Polymarket prices in a 96% probability of no Fed rate cuts in 2026 ($8.7M liquidity). Fed Governor Barr is renewing rate-increase calls. Soft-landing remains consensus (8% US recession probability by YE2026). AI infrastructure boom is emerging as a notable inflation driver, particularly relevant for industrial automation vendors. EMR is in a FY-end blackout period (Sep 30) with no company-specific news expected until the FY2026 print in November.